An extension study is not simply a longer version of the original randomized comparison. It usually follows people who completed the earlier phase and chose to continue. Those entry conditions affect what the later observations can establish.
In the RECONNECT open-label extension, 684 participants enrolled and 272 completed the extension. Eligibility came from core-trial completers without specified serious adverse events, and the later phase was open label. The authors reported sustained symptom improvements among the observed treatment experience, using descriptive analyses.
These details matter because the continuation group is selected. People who found the earlier experience unacceptable may not enter, and those who stop later may differ from those who remain. The resulting observations cannot be assumed to represent every person who originally considered or started treatment.
Open label also means participants know what they are receiving. Expectations and reporting can therefore differ from a blinded comparison. That does not invalidate the experience, but it limits a causal statement that the medicine alone explains every later change.
Attrition should be visible beside the duration. A headline emphasizing a year of follow-up while omitting how many people completed it can give an exaggerated impression of evidence density. Reasons for stopping are also important; tolerability, perceived benefit and unrelated circumstances may have different implications.
The study does not supply an unlimited-use permission or establish that loss of response can be fixed by increasing exposure. It does not authenticate a research vial or evaluate every combination discussed online. A clinical review needs the person's actual response and safety history, not only the longest follow-up in the literature.
The balanced conclusion is that the extension contributes useful longer-term observations for a selected HSDD population. It is neither proof that everyone will benefit indefinitely nor evidence that repeated use necessarily fails. For prescribed treatment, ongoing benefit and burdens should be reviewed with the clinician. This article offers no repeated-use schedule; it explains what the extension's design allows a reader to conclude.